Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine

Journal of Controlled Release

Volumn 174, Issue 1, 2014, Pages 51-62

  Patil, Harshad P ^a   Murugappan, Senthil ^b   Ter Veer, Wouter ^a   Meijerhof, Tjarko ^a   De Haan, Aalzen ^a   Frijlink, Henderik W ^b   Wilschut, Jan ^a   Hinrichs, Wouter L J ^b   Huckriede, Anke ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

IgA; Inhalation; Protection; Spray freeze drying; Whole inactivated virus

Indexed keywords

IGA; INACTIVATED VIRUS; INHALATION; PROTECTION; SPRAY-FREEZE-DRYING;

ANTIBODIES; ANTIGEN-ANTIBODY REACTIONS; BINDING ENERGY; CELL CULTURE; IMMUNIZATION; LOW TEMPERATURE DRYING; MAMMALS; POROUS MATERIALS; VIRUSES;

VACCINES;

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INULIN; PHOSPHORYL LIPID A; SUBUNIT VACCINE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DRUG FORMULATION; EVALUATION; FEMALE; FREEZE DRYING; HEMAGGLUTINATION; HEMAGGLUTINATION INHIBITION; HUMORAL IMMUNITY; IMMUNOGLOBULIN PRODUCTION; INFLUENZA VIRUS; LIQUID; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PARTICLE SIZE; POWDER; PRIORITY JOURNAL; RECEPTOR BINDING; VACCINATION; VIRUS INACTIVATION; VIRUS TITRATION; WEIGHT REDUCTION;

IGA; INHALATION; PROTECTION; SPRAY-FREEZE-DRYING; WHOLE INACTIVATED VIRUS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INHALATION; ANIMALS; ANTIBODIES, VIRAL; BRONCHOALVEOLAR LAVAGE FLUID; DOGS; FEMALE; HEMAGGLUTINATION TESTS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INTERFERON-GAMMA; LIPID A; LUNG; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED BALB C; NASAL MUCOSA;

EID: 84888313744     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.11.013     Document Type: Article

References (46)

1. Report of the WHO Pandemic Influenza A(H1N1) Vaccine Deployment Initiative 2010 World Heal. Organization (http://whqlibdoc.who.int/publications/ 2012/9789241564427-eng.pdf)
2. K. Subbarao, and T. Joseph Scientific barriers to developing vaccines against a (Pubitemid 46480953)
3. N.P.a.S. Johnson, and J. Mueller Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic Bull. Hist. Med. 76 2002 105 115
4. N.M. Ferguson, D.A.T. Cummings, C. Fraser, J.C. Cajka, P.C. Cooley, and D.S. Burke Strategies for mitigating an influenza pandemic Nature 442 2006 448 452 (Pubitemid 44264793)
5. W.H.O. Meeting, Main operational Lessons Learnt From the WHO Pandemic Influenza A (H1N1) Vaccine Deployment Initiative Report of a WHO Meeting 2010 World Heal. Organ. 1 28
6. J.-P. Amorij, W.L. Hinrichs, H.W. Frijlink, J.C. Wilschut, and A. Huckriede Needle-free influenza vaccination Lancet Infect. Dis. 10 2010 699 711
7. M.-E. Hogan, A. Kikuta, and A. Taddio A systematic review of measures for reducing injection pain during adult immunization Vaccine 28 2010 1514 1521
8. Y. Nir, A. Paz, E. Sabo, and I. Potasman Fear of injections in young adults: prevalence and associations Am. J. Trop. Med. Hyg. 68 2003 341 344 (Pubitemid 38240525)
9. R.A. Kleinknecht Acquisition of blood, injury, and needle fears and phobias Behav. Res. Ther. 32 1994 817 823 (Pubitemid 24291011)
10. H.J. de Heer, H. Hammad, M. Kool, and B.N. Lambrecht Dendritic cell subsets and immune regulation in the lung Semin. Immunol. 17 2005 295 303 (Pubitemid 40981934)
11. V. Saluja, J.-P. Amorij, J.C. Kapteyn, A.H. de Boer, H.W. Frijlink, and W.L.J. Hinrichs A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation J. Control. Release 144 2010 127 133
12. F. Geeraedts, V. Saluja, W. ter Veer, J.-P. Amorij, H.W. Frijlink, and J. Wilschut Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures AAPS J. 12 2010 215 222
13. F. Blank, P. Stumbles, and C. von Garnier Opportunities and challenges of the pulmonary route for vaccination Expert Opin. Drug Deliv. 8 2011 547 563
14. R.H. Waldman, J.O. Bond, L.P. Levitt, E.C. Hartwig, E.C. Prather, and R.L. Baratta An evaluation of influenza immunization: influence of route of administration and vaccine strain Bull. World Health Organ. 41 1969 543 548
15. W. Haigh, and R.W. Howell The efficacy of the A2/Aichi/68 strain in inhaled influenza immunisation against the A/England/42/72 variant J. Soc. Occup. Med. 23 1973 125 127
16. A. Minne, J. Louahed, S. Mehauden, B. Baras, J.-C. Renauld, and R. Vanbever The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response Immunology 122 2007 316 325 (Pubitemid 47556468)
17. J.-P. Amorij, V. Saluja, A.H. Petersen, W.L.J. Hinrichs, A. Huckriede, and H.W. Frijlink Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice Vaccine 25 2007 8707 8717 (Pubitemid 350199597)
18. S.A.L. Audouy, G. van der Schaaf, W.L.J. Hinrichs, H.W. Frijlink, J. Wilschut, and A. Huckriede Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization Vaccine 29 2011 4345 4352
19. K.B. Renegar, P.A. Small, L.G. Boykins, and P.F. Wright Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract J. Immunol. 173 2004 1978 1986 (Pubitemid 38971634)
20. V.C. Huber, R.M. McKeon, M.N. Brackin, L.A. Miller, R. Keating, and S.A. Brown Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza Clin. Vaccine Immunol. 13 2006 981 990 (Pubitemid 44518965)
21. S. Murugappan, H.P. Patil, G. Kanojia, W. Ter Veer, T. Meijerhof, and H.W. Frijlink Physical and immunogenic stability of spray freeze dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran or a mixture of dextran and trehalose as protectants Eur. J. Pharm. Biopharm. 2013 10.1016/j.ejpb.2013.07.018
22. R.L. Coffman, A. Sher, and R.A. Seder Vaccine adjuvants: putting innate immunity to work Immunity 33 2010 492 503
23. E.M.Y. Moresco, D. LaVine, and B. Beutler Toll-like receptors Curr. Biol. 21 2011 R488 R493
24. D. Parker, and A. Prince Innate immunity in the respiratory epithelium Am. J. Respir. Cell Mol. Biol. 45 2011 189 201
25. J.R. Baldridge, Y. Yorgensen, J.R. Ward, and J.T. Ulrich Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration Vaccine 18 2000 2416 2425 (Pubitemid 30156813)
26. T. Kamphuis, M. Shafique, T. Meijerhof, T. Stegmann, J. Wilschut, and A. de Haan Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats Vaccine 31 2013 2169 2176
27. C.R. Casella, and T.C. Mitchell Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant Cell. Mol. Life Sci. 65 2008 3231 3240
28. A. Monie, C.F. Hung, R. Roden, and T.C. Wu Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer Biologics 2 2008 97 105
29. S.P. Kasturi, I. Skountzou, R.A. Albrecht, D. Koutsonanos, T. Hua, and H.I. Nakaya Programming the magnitude and persistence of antibody responses with innate immunity Nature 470 2011 543 547
30. N.Y. Lycke, and R. Coico Measurement of immunoglobulin synthesis using the ELISPOT assay Curr. Protoc. Immunol. 2001 (Chapter 7, Unit 7.14)
31. G.S. Zijlstra, M. Rijkeboer, D. Jan van Drooge, M. Sutter, W. Jiskoot, and M. van de Weert Characterization of a cyclosporine solid dispersion for inhalation AAPS J. 9 2007 E190 E199
32. T. Sou, E.N. Meeusen, M. de Veer, D.A.V. Morton, L.M. Kaminskas, and M.P. McIntosh New developments in dry powder pulmonary vaccine delivery Trends Biotechnol. 29 2011 191 198
33. N.R. Labiris, and M.B. Dolovich Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications Br. J. Clin. Pharmacol. 56 2003 588 599 (Pubitemid 37491710)
34. M.S. Pereira, P. Chakraverty, G.C. Schild, M.T. Coleman, and W.R. Dowdle Prevalence of antibody to current influenza viruses and effect of vaccination on antibody response Br. Med. J. 4 1972 701 703
35. D. Hobson, R.L. Curry, A.S. Beare, and A. Ward-Gardner The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses J. Hyg. (Lond.) 70 1972 767 777
36. S.P. Sullivan, D.G. Koutsonanos, M. Del Pilar Martin, J.W. Lee, V. Zarnitsyn, and S.-O. Choi Dissolving polymer microneedle patches for influenza vaccination Nat. Med. 16 2010 915 920
37. J.M. Monteiro, C. Harvey, and G. Trinchieri Role of interleukin-12 in primary influenza virus infection J. Virol. 72 1998 4825 4831 (Pubitemid 28215659)
38. G. Zhou, S.W.W. Juang, and K.P. Kane NK cells exacerbate the pathology of influenza virus infection in mice Eur. J. Immunol. 43 2013 929 938
39. F. Geeraedts, L. Bungener, J. Pool, W. ter Veer, J. Wilschut, and A. Huckriede Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs Influenza Other Respir. Viruses 2 2008 41 51
40. F. Geeraedts, N. Goutagny, V. Hornung, M. Severa, A. de Haan, and J. Pool Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling PLoS Pathog. 4 2008 e1000138
41. C.R. Alving, M. Rao, N.J. Steers, G.R. Matyas, and A.V. Mayorov Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines Expert Rev. Vaccines 11 2012 733 744
42. J. Dijkstra, R. Bron, J. Wilschut, A. de Haan, and J.L. Ryan Activation of murine lymphocytes by lipopolysaccharide incorporated in fusogenic, reconstituted influenza virus envelopes (virosomes) J. Immunol. 157 1996 1028 1036
43. N.K. Childers, K.L. Miller, G. Tong, J.C. Llarena, T. Greenway, and J.T. Ulrich Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen Infect. Immun. 68 2000 5509 5516
44. T. Kamphuis, T. Meijerhof, T. Stegmann, J. Lederhofer, J. Wilschut, and A. de Haan Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice PLoS One 7 2012 e36812
45. D.S. Southam, M. Dolovich, P.M. O'Byrne, and M.D. Inman Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia Am. J. Physiol. Lung Cell. Mol. Physiol. 282 2002 L833 L839
46. T. Onodera, Y. Takahashi, Y. Yokoi, M. Ato, Y. Kodama, and S. Hachimura Memory B cells in the lung participate in protective humoral immune responses to pulmonary influenza virus reinfection Proc. Natl. Acad. Sci. U. S. A. 109 2012 2485 2490